Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?
Open Access
- 2 June 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1870289
Abstract
The OX40/OX40L axis entered clinical development in atopic dermatitis with a strong biological rationale and early signs of durable activity. However, as the treatment landscape evolved, questions emerged about whether the magnitude of monotherapy benefit was sufficient relative to established and emerging therapies. The discontinuation of rocatinlimab after confirmed and suspected cutaneous Kaposi’s sarcoma cases, together with two cumulative cases reported in the amlitelimab program in patients with known risk factors, has changed the discussion from early promise to mechanism, risk, and therapeutic strategy. Although a causal link between OX40/OX40L modulation and Kaposi’s sarcoma remains unproven, available human genetic and experimental observations make the association biologically plausible but mechanistically unresolved. The central challenge is now to determine how the axis can be targeted, in which patients, and in what therapeutic context, to maximize clinical benefit while managing risk. Rather than signaling the end of the axis in atopic dermatitis, Kaposi’s sarcoma may instead mark the limits of a first-generation development strategy and the beginning of a more selective approach built around molecule design, therapeutic context, and prospective risk mitigation.Keywords
This publication has 24 references indexed in Scilit:
- A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b StudyDermatology and Therapy, 2025
- Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimabArchives of Dermatological Research, 2024
- OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic TargetAmerican Journal of Clinical Dermatology, 2024
- An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b studyThe Lancet, 2022
- Atopic dermatitisThe Lancet, 2020
- Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitisJournal of Dermatological Science, 2020
- Atopic dermatitis endotypes and implications for targeted therapeuticsJournal of Allergy and Clinical Immunology, 2019
- Atopic dermatitisThe Lancet, 2016
- Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitisJournal of Allergy and Clinical Immunology, 2013
- Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsetsJournal of Allergy and Clinical Immunology, 2011